Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.63 |
| ▸ | MLNR | O43193 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419230 | 1.00 | ESR1 (0.69) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL4165462 | 0.91 | ESR1 (0.79) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL637818 | 0.91 | ESR1 (0.79) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL30103459 | 0.91 | ESR1 (0.79) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL3420019 | 0.90 | ESR1 (0.79) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL3416547 | 0.90 | ESR1 (0.79) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL22692809 | 0.90 | ESR1 (0.77) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL28751139 | 0.90 | ESR1 (0.58) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL3419820 | 0.89 | ESR1 (0.82) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL4163410 | 0.89 | ESR1 (0.75) | ESR1ESR2MLNRABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051179-B1 | ANTI-ESTROGEN PLUS PROGESTIN CONTAINING ORAL CONTRACEPTIVES | WYETH CORP (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040110824-A1 | 2-Phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH | 2004-06-10 | — | — | US | claimed |
| US-20040110823-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH | 2004-06-10 | — | — | US | claimed |
| US-20030130274-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)benzyl-indoles as estrogenic agents | WYETH | 2003-07-10 | — | — | US | claimed |
| US-20020061875-A1 | Anti-estrogen plus progestin containing oral contraceptives | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-23 | — | — | US | claimed |
| US-20020028805-A1 | Methods of inhibiting uterotrophic effects of estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | claimed |
| US-20020016318-A1 | Methods of treating breast disorders | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-07 | — | — | US | claimed |
| US-6326392-B1 | ADMINISTERING MIXTURE | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-04 | — | — | US | claimed |
| US-6326367-B1 | THERAPY FOR OVARIAN CANCER | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-04 | — | — | US | claimed |
| EP-0802183-B1 | Estrogenic agents | AMERICAN HOME PROD (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010021719-A1 | 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents | WYETH | 2001-09-13 | — | — | US | claimed |
| US-6232307-B1 | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)-INDOLE COMPOUNDS USEFUL AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-15 | — | — | US | claimed |
| US-6225308-B1 | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)-INDOLE COMPOUNDS WHICH ARE USEFUL AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-01 | — | — | US | claimed |
| EP-1051179-A2 | ANTI-ESTROGEN PLUS PROGESTIN CONTAINING ORAL CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-15 | — | — | EP | claimed |
| US-6127404-A | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)INDOLE COMPOUNDS USEFUL AS ESTROGEN AGONISTS/ANTAGONISTS; OSTEOPOROSIS; ANTICHOLESTEROL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-03 | — | — | US | claimed |
| US-5998402-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-07 | — | — | US | claimed |
| WO-1999024027-A2 | ANTI-ESTROGEN PLUS PROGESTIN CONTAINING ORAL CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-05-20 | — | — | WO | claimed |
| EP-0802183-A1 | Estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-22 | — | — | EP | claimed |
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2014-11-06 | — | — | US | disclosed |
| EP-0802183-A1 | Estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021719-A1 | 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885MLNR 874/4885 |
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | ESR2, ESR1, CYP19A1 | ESR1 2/4885ESR2 1/4885MLNR 1321/4885 |
| US-20030130274-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)benzyl-indoles as estrogenic agents | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885MLNR 1976/4885 |
| US-20040110824-A1 | 2-Phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885MLNR 1970/4885 |
| US-20020028805-A1 | Methods of inhibiting uterotrophic effects of estrogenic agents | LHCGR, GPER1, MTNR1A | ESR1 8/4885ESR2 18/4885MLNR 31/4885 |
| US-20040110823-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885MLNR 1947/4885 |
| US-20020016318-A1 | Methods of treating breast disorders | BRCA1, PYM1, HSD3B1 | ESR1 16/4885ESR2 48/4885MLNR 1310/4885 |
| US-20020061875-A1 | Anti-estrogen plus progestin containing oral contraceptives | SHBG, CYP19A1, PGRMC2 | ESR1 17/4885ESR2 8/4885MLNR 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.